Tags

Type your tag names separated by a space and hit enter

Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
Cephalalgia 1999; 19(7):676-83; discussion 626C

Abstract

In a multicenter study, a long-term analysis was made of the efficacy, safety, and tolerability of subcutaneous (s.c.) sumatriptan in the acute treatment of migraine attacks over a period of up to 18 months. A total of 2263 patients took part in the study, all able to perform their own acute treatment of migraine attacks at home by s.c. administration of 6 mg of sumatriptan. A headache diary was used by each patient to record the various migraine parameters before the injection and 1 h and 2 h after it. A total of 43,691 attacks were treated and analyzed during the study period from October 1991 to June 1993. Therapy was successful in 89.5% of attacks. Freedom from headache was achieved in 71.0% of cases. In 22.7% of the attacks a second injection was administered on recurrence of the headache; 82.9% of the patients achieved an intraindividual therapy success rate ranging from over 80% to 100%. In the course of treatment there was no change in either the therapy success rate or in the frequency of attacks. Some 4.9% of the patients withdrew from the study because of insufficient efficacy or adverse events. A total of 44.5% of patients reported adverse events, and these were rated serious in the case of 1.7%. S.c. administration of sumatriptan for acute migraine therapy is an effective treatment method, with reliable action, that can be used with good tolerability provided the contraindications are taken into account.

Authors+Show Affiliations

Neurologisch-verhaltensmedizinische Schmerzklinik Kiel, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

10524662

Citation

Göbel, H, et al. "Open-labeled Long-term Study of the Efficacy, Safety, and Tolerability of Subcutaneous Sumatriptan in Acute Migraine Treatment." Cephalalgia : an International Journal of Headache, vol. 19, no. 7, 1999, pp. 676-83; discussion 626.
Göbel H, Heinze A, Stolze H, et al. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia. 1999;19(7):676-83; discussion 626.
Göbel, H., Heinze, A., Stolze, H., Heinze-Kuhn, K., & Lindner, V. (1999). Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia : an International Journal of Headache, 19(7), pp. 676-83; discussion 626.
Göbel H, et al. Open-labeled Long-term Study of the Efficacy, Safety, and Tolerability of Subcutaneous Sumatriptan in Acute Migraine Treatment. Cephalalgia. 1999;19(7):676-83; discussion 626. PubMed PMID: 10524662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. AU - Göbel,H, AU - Heinze,A, AU - Stolze,H, AU - Heinze-Kuhn,K, AU - Lindner,V, PY - 1999/10/19/pubmed PY - 1999/10/19/medline PY - 1999/10/19/entrez SP - 676-83; discussion 626 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 19 IS - 7 N2 - In a multicenter study, a long-term analysis was made of the efficacy, safety, and tolerability of subcutaneous (s.c.) sumatriptan in the acute treatment of migraine attacks over a period of up to 18 months. A total of 2263 patients took part in the study, all able to perform their own acute treatment of migraine attacks at home by s.c. administration of 6 mg of sumatriptan. A headache diary was used by each patient to record the various migraine parameters before the injection and 1 h and 2 h after it. A total of 43,691 attacks were treated and analyzed during the study period from October 1991 to June 1993. Therapy was successful in 89.5% of attacks. Freedom from headache was achieved in 71.0% of cases. In 22.7% of the attacks a second injection was administered on recurrence of the headache; 82.9% of the patients achieved an intraindividual therapy success rate ranging from over 80% to 100%. In the course of treatment there was no change in either the therapy success rate or in the frequency of attacks. Some 4.9% of the patients withdrew from the study because of insufficient efficacy or adverse events. A total of 44.5% of patients reported adverse events, and these were rated serious in the case of 1.7%. S.c. administration of sumatriptan for acute migraine therapy is an effective treatment method, with reliable action, that can be used with good tolerability provided the contraindications are taken into account. SN - 0333-1024 UR - https://www.unboundmedicine.com/medline/citation/10524662/Open_labeled_long_term_study_of_the_efficacy_safety_and_tolerability_of_subcutaneous_sumatriptan_in_acute_migraine_treatment_ L2 - http://journals.sagepub.com/doi/full/10.1046/j.1468-2982.1999.019007676.x?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -